The changing face of Klebsiella pneumoniae carbapenemase: in-vivo mutation in patient with chest infection

Lancet. 2022 Jun 11;399(10342):2226. doi: 10.1016/S0140-6736(22)01011-X.

Authors

Siquan Shen¹, Qingyu Shi¹, Fupin Hu²

Affiliations

¹ Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
² Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China. Electronic address: hufupin@fudan.edu.cn.

PMID: 35691325
DOI: 10.1016/S0140-6736(22)01011-X

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bacterial Proteins / genetics
Humans
Klebsiella pneumoniae* / genetics
Mutation
Respiratory Tract Infections*
beta-Lactamases / genetics

Substances

Anti-Bacterial Agents
Bacterial Proteins
beta-Lactamases
carbapenemase